Edition:
United States

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

41.20USD
21 Apr 2017
Change (% chg)

-- (--)
Prev Close
$41.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
118,285
52-wk High
$51.80
52-wk Low
$12.61

Latest Key Developments (Source: Significant Developments)

Aerie Pharmaceuticals reports positive topline safety and efficacy results for rhopressatm
Wednesday, 12 Apr 2017 04:01pm EDT 

Aerie Pharmaceuticals Inc : Aerie Pharmaceuticals reports positive rocket 4 six-month topline safety and efficacy results for rhopressatm (netarsudil ophthalmic solution) 0.02pct . Aerie Pharmaceuticals -most common rhopressa adverse event was hyperemia, which was reported in about 48 percent of patients, 75 percent of which was mild .Aerie Pharmaceuticals Inc says 12-month safety data from mercury 1 are expected in Q3 of this year.  Full Article

Aerie Pharmaceuticals reports Q4 GAAP loss per share of $0.87
Tuesday, 7 Mar 2017 04:01pm EST 

Aerie Pharmaceuticals Inc : Aerie Pharmaceuticals reports fourth quarter and full year 2016 financial results and provides business update . Q4 adjusted loss per share $0.72 . Q4 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S . Q4 GAAP loss per share $0.87 .Rhopressa NDA resubmitted, and readouts from rocket 4 and mercury 2 on track for Q2 of 2017.  Full Article

Aerie Pharmaceuticals announces resubmission of NDA for rhopressatm 0.02 pct
Wednesday, 1 Mar 2017 06:30am EST 

Aerie Pharmaceuticals Inc : Aerie Pharmaceuticals announces resubmission of NDA for rhopressatm (netarsudil ophthalmic solution) 0.02 pct . Aerie Pharmaceuticals Inc - pending approval, we anticipate product launch in Q2 of 2018 for rhopressa . Aerie Pharmaceuticals - continue to expect in Q2 of 2017, readout of six-month safety and efficacy data for rhopressa Phase 3 registration trial .Aerie Pharmac - anticipate in Q2'17, readout of 90-day efficacy data from mercury 2, Second Phase 3 registration trial for roclatan 0.02 pct/0.005 pct.  Full Article

Aerie Pharmaceuticals entered into a lease agreement with Industrial Development Agency of Ireland
Monday, 9 Jan 2017 06:30am EST 

Aerie Pharmaceuticals Inc : Aerie Pharmaceuticals Inc - Entered into a lease agreement with Industrial Development Agency (IDA) of Ireland for a new manufacturing plant . Aerie Pharmaceuticals Inc - Estimated project-wide construction and equipment costs are expected to total approximately $25 million .Aerie Pharmaceuticals Inc - If approved, commercial product supply of Rhopressa(tm) from plant is expected to be available by 2020..  Full Article

Aerie Pharmaceuticals provides update on timing of NDA filing for Rhopressa
Friday, 23 Dec 2016 06:30am EST 

Aerie Pharmaceuticals Inc : Aerie now expects to resubmit Rhopressa(TM)NDA filing near end of Q1 of 2017 . Florida facility will not be ready for pre-approval inspection by FDA until end of February 2017 . Aerie Pharmaceuticals Inc - Delay does not result from any new findings, but rather additional time needed to complete validation of new equipment .Aerie Pharmaceuticals provides update on timing of NDA filing for Rhopressatm (netarsudil ophthalmic solution) 0.02%.  Full Article

Aerie Pharma completes enrollment of mercury 2 phase 3 registration trial of roclatan
Wednesday, 7 Dec 2016 06:30am EST 

Aerie Pharmaceuticals Inc: Aerie pharmaceuticals completes enrollment of mercury 2 phase 3 registration trial of roclatan(tm) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% . Aerie pharmaceuticals-mercury 2,which commenced in march 2016, is 90-day registration trial with a topline efficacy readout expected in q2 of 2017 . Aerie pharmaceuticals inc - trial on track for topline 90-day efficacy readout in q2 2017 . Aerie pharmaceuticals inc - continue to expect to file an nda for roclatan(tm) ophthalmic solution near year-end 2017 .Aerie pharmaceuticals inc - plans to commence in first half of 2017 a third phase 3 registration trial for roclatan(tm), named mercury 3.  Full Article

Aerie pharmaceuticals updates full-year 2016 cash burn guidance
Thursday, 22 Sep 2016 06:03am EDT 

Aerie Pharmaceuticals Inc : Expects cash and cash equivalents to total approximately $230 million as of December 31, 2016 . Updated full-year 2016 cash burn guidance to approximately $85 million, an increase from previous guidance of $75 million .Updated guidance reflects initiatives like start-up of clinical trials in Japan, construction of manufacturing plant in Ireland.  Full Article

Aerie Pharmaceuticals submits NDA to U.S. Food and drug administration for Rhopressa
Tuesday, 6 Sep 2016 04:01pm EDT 

Aerie Pharmaceuticals Inc :Submits new drug application to U.S. Food and Drug Administration for Rhopressa (netarsudil ophthalmic solution) 0.02 percent.  Full Article

Aerie pharmaceuticals reports Q2 2016 financial results and provides business update
Wednesday, 3 Aug 2016 04:49pm EDT 

Aerie Pharmaceuticals Inc : Aerie Pharmaceuticals reports second quarter 2016 financial results and provides business update . Q2 GAAP loss per share $0.87 . Q2 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S . Q2 adjusted loss per share $0.72 .Aerie Pharmaceuticals Inc says remains on track to file its NDA for Rhopressa(TM)(Netarsudil Ophthalmic Solution) 0.02% in Q3 of 2016.  Full Article

Aerie Pharma completes enrollment of phase 3 clinical trial of eye drug Rhopressa
Thursday, 16 Jun 2016 06:30am EDT 

Aerie Pharmaceuticals Inc : Trial on track for topline 90-day interim efficacy readout in q4 2016 . Rocket 4 designed for eu filing; not required for us nda filing . Expect to file for european approval of rhopressa in second half of 2017 .Aerie pharmaceuticals completes enrollment of rocket 4 phase 3 clinical trial of rhopressatm (netarsudil ophthalmic solution) 0.02%.  Full Article

More From Around the Web

BRIEF-Aerie Pharmaceuticals reports positive topline safety and efficacy results for rhopressatm

* Aerie Pharmaceuticals reports positive rocket 4 six-month topline safety and efficacy results for rhopressatm (netarsudil ophthalmic solution) 0.02pct